References

Adela, R., & Banerjee, S. K. (2015). GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. Journal of diabetes research, 2015.  https://doi.org/10.1155/2015/490842.

Ahmeda, E. S. (2020). Association between Growth Differentiation Factor 15 and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus.  https://doi.org/10.1111/dom.14553.

Al Ghuraibawi, Z. A. G., Sharquie, I. K., & Gorial, F. I. (2023). A novel link of serum IL-39 levels in patients with rheumatoid arthritis. Iraqi Journal of Science, 1651-1661.‏

Al_Badran, A. H. K., Algabri, H. C., Al Saeedi, K. R. H., & Alqazzaz, A. M. (2022). Incidence of rheumatoid arthritis at Marjan teaching hospital in Babylon, Iraq (2014–2019). Medical Journal of Babylon, 19(3), 358-361.‏

Alattabi, A. S., Abood Jaber, M. A., & Zenki, F. A. (2019). Comparison of ACPA and Anti RA 33 Ab as Prognostic Factors in Patients with Rheumatoid Arthritis. Indian Journal of Public Health Research & Development, 10(5).‏

Albabawaty, N. S., Majid, A. Y., Alosami, M. H., & Mahmood, H. G. (2020). Role of high sensitivity C-Reactive protein and some of heavy metals in patients with rheumatoid arthritis. Ann Trop Med Public Health, 23, 16.‏

Al-Bedri, K., Al-Quriashi, N. K. M., Gorial, F. I., & Younis, H. A. (2016). Ocular manifestations in rheumatoid arthritis: a descriptive cross-sectional study from Iraq. J Nat Sci Res, 6(8), 57.‏

Al-dabbagh, n. Y., & hashim, z. A. (2018). Evaluation of anti-ccp antibodies and rheumatoid factor for the laboratory diagnosis of rheumatoid arthritis. Duhok Medical Journal, 12(1), 41-54.‏

Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham III, C. O., ... & Hawker, G. (2010). 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & rheumatism, 62(9), 2569-2581.‏

Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham III, C. O., ... & Hawker, G. (2010). 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & rheumatism, 62(9), 2569-2581.‏

Ali, G. A., & Abbas, T. S. (2022). Anti-Carbamylated Protein Antibody Test Accuracy In Some Iraqi Patients With Rheumatoid Arthritis. Medical Science Journal for Advance Research, 3(4), 171-178.‏

Ali, G. A., & Al-Turaihi, T. S. A. (2022). Identification serum CXCL13 chemokine as a novel biomarker in diagnosis of rheumatoid arthritis. HIV Nursing, 22(2), 3686-3690.‏

Alifu, J., Xiang, L., Zhang, W., Qi, P., Chen, H., Liu, L., ... & Che, W. (2023). Association between the atherogenic index of plasma and adverse long-term prognosis in patients diagnosed with chronic coronary syndrome. Cardiovascular Diabetology, 22(1), 255.‏

Allain, C. C., Poon, L. S., Chan, C. S., Richmond, W. F. P. C., & Fu, P. C. (1974). Enzymatic determination of total serum cholesterol. Clinical chemistry, 20(4), 470-475.‏

Al-Marri, M. R. H. A., & Kirkpatrick, M. B. (2000). Erythrocyte sedimentation rate in childhood tuberculosis: is it still worthwhile?. The International Journal of Tuberculosis and Lung disease, 4(3), 237-239.‏

Almurshedi, S. M., Alasady, R. A. A., Alsherees, H. A., Almohana, A. M., Aljayashi, K. G., & Almudhaffer, D. H. (2023). The Role of Galectin-3 in The Diagnosis and Evaluation of Disease Activity in Rheumatoid Arthritis. Jurnal Biota, 9(2), 118-126.‏

Almutairi, K. B., Nossent, J. C., Preen, D. B., Keen, H. I., & Inderjeeth, C. A. (2021). The prevalence of rheumatoid arthritis: a systematic review of population-based studies. The Journal of rheumatology, 48(5), 669-676.‏

Almutairi, K., Nossent, J., Preen, D., Keen, H., & Inderjeeth, C. (2021). The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatology international, 41(5), 863-877.‏

Al-Rawi, Z. S., Alazzawi, A. J., Alajili, F. M., & Alwakil, R. (1978). Rheumatoid arthritis in population samples in Iraq. Annals of the rheumatic diseases, 37(1), 73-75.‏

Alwan, I. T., & Ghali, K. H. (2021). The correlation between accp with developing, progression and activity of rheumatoid arthritis. Annals of the Romanian Society for Cell Biology, 408-418.‏

Arkoumani, M., Papadopoulou-Marketou, N., Nicolaides, N. C., Kanaka-Gantenbein, C., Tentolouris, N., & Papassotiriou, I. (2020). The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update. Critical Reviews in Clinical Laboratory Sciences, 57(2), 114-125.‏

Asrih, M., Wei, S., Nguyen, T. T., Yi, H. S., Ryu, D., & Gariani, K. (2023). Overview of growth differentiation factor 15 in metabolic syndrome. Journal of Cellular and Molecular Medicine, 27(9), 1157-1167.‏

Attar, S. M., & Al Ghamdi, A. (2010). Radiological changes in rheumatoid arthritis patients at a teaching hospital in Saudi Arabia. EMHJ-Eastern Mediterranean Health Journal, 16 (9), 953-957, 2010.‏

Bag-Ozbek, A., & Giles, J. T. (2015). Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship?. Current allergy and asthma reports, 15, 1-10.‏

Bao, X., Borné, Y., Muhammad, I. F., Nilsson, J., Lind, L., Melander, O., ... & Engström, G. (2019). Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer–Cardiovascular Cohort. Diabetologia, 62, 78-86.‏

Bemis, E. A., Demoruelle, M. K., Seifert, J. A., Polinski, K. J., Weisman, M. H., Buckner, J. H., ... & Norris, J. M. (2021). Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Annals of the rheumatic diseases, 80(2), 154-161.‏

Blasco, M. A. (2007). Telomere length, stem cells and aging. Nature chemical biology, 3(10), 640-649.‏

Blyszczuk, P., & Szekanecz, Z. (2020). Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. RMD open, 6(1), e001032.‏

Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., ... & Breit, S. N. (1997). MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proceedings of the National Academy of Sciences, 94(21), 11514-11519.‏

Böttiger, Svedberg, C. A. (1967). Normal erythrocyte sedimentation rate and age. British medical journal, 2(5544), 85.‏

Brigden, M. L. (1999). Clinical utility of the erythrocyte sedimentation rate. American family physician, 60(5), 1443-1450.‏

Brown, D. A., Moore, J., Johnen, H., Smeets, T. J., Bauskin, A. R., Kuffner, T., ... & Breit, S. N. (2007). Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis & Rheumatism, 56(3), 753-764.‏

Castrejón, I., Ortiz, A. M., Garcia-Vicuna, R., Lopez-Bote, J. P., Humbría, A., Carmona, L., & Gonzalez-Alvaro, I. (2008). Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis?. Clinical & Experimental Rheumatology, 26(5), 769.‏

Conforti, A., Di Cola, I., Pavlych, V., Ruscitti, P., Berardicurti, O., Ursini, F., ... & Cipriani, P. (2021). Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmunity reviews, 20(2), 102735.‏

Coutant, F., & Miossec, P. (2020). Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Current opinion in rheumatology, 32(1), 57-63.‏

Crowson, C. S., Rahman, M. U., & Matteson, E. L. (2009). Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. The Journal of Rheumatology, 36(8), 1606-1610.‏

Cure, E., Icli, A., Uslu, A. U., Sakiz, D., Cure, M. C., Baykara, R. A., ... & Kucuk, A. (2018). Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis: AIP associate with cIMT in AS. Clinical rheumatology, 37, 1273-1280.‏

Deane, K. D., Demoruelle, M. K., Kelmenson, L. B., Kuhn, K. A., Norris, J. M., & Holers, V. M. (2017). Genetic and environmental risk factors for rheumatoid arthritis. Best practice & research Clinical rheumatology, 31(1), 3-18.‏

Dessie, G. (2022). Association of atherogenic indices with C-reactive protein and risk factors to assess cardiovascular risk in rheumatoid arthritis patient at Tikur Anbessa Specialized Hospital, Addis Ababa. Plos one, 17(6), e0269431.‏

Dessie, G., Tadesse, Y., Demelash, B., & Genet, S. (2020). Assessment of serum lipid profiles and high-sensitivity C-reactive protein among patients suffering from rheumatoid arthritis at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a cross-sectional study. Open Access Rheumatology: Research and Reviews, 223-232.‏

di Candia, A. M., de Avila, D. X., Moreira, G. R., Villacorta, H., & Maisel, A. S. (2021). Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases. American Heart Journal Plus: Cardiology Research and Practice, 9, 100046.‏

Dobiasova, M. (2006). AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitrni lekarstvi, 52(1), 64-71.‏

Doerstling, S., Hedberg, P., Öhrvik, J., Leppert, J., & Henriksen, E. (2018). Growth differentiation factor 15 in a community-based sample: age-dependent reference limits and prognostic impact. Upsala journal of medical sciences, 123(2), 86-93.‏

Drechsler, M., Megens, R. T., van Zandvoort, M., Weber, C., & Soehnlein, O. (2010). Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation, 122(18), 1837-1845.‏

El Shebiny, E., El Sabbagh, A., Shoeib, S., Elnoamany, S., Wahb, R., Mohamed, S., ... & Zahran, E. (2022). Growth differentiation factor 15: a possible link between rheumatoid arthritis and atherosclerosis. Menoufia Medical Journal, 35(4), 1787.‏

Elbarky, E. M., Hussien, M. I., Elgazzar, N. M., Mabrouk, M. M., & Elsaadany, H. M. (2021). Serum growth differentiation factor-15 (GDF-15) level in behcet's disease patients: Relation to clinical characteristics, musculoskeletal ultrasound findings and disease activity. The Egyptian Rheumatologist, 43(3), 261-266.‏

Erum, U., Ahsan, T., & Khowaja, D. (2017). Lipid abnormalities in patients with Rheumatoid Arthritis. Pakistan journal of medical sciences, 33(1), 227.‏

Esalatmanesh, K., Fayyazi, H., Esalatmanesh, R., & Khabbazi, A. (2020). The association between serum levels of growth differentiation factor-15 and rheumatoid arthritis activity. International Journal of Clinical Practice, 74(9), e13564.‏

Figus, F. A., Piga, M., Azzolin, I., McConnell, R., & Iagnocco, A. (2021). Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmunity reviews, 20(4), 102776.‏

Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry, 18(6), 499-502.‏

Fujita, Y., Taniguchi, Y., Shinkai, S., Tanaka, M., & Ito, M. (2016). Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatrics & gerontology international, 16, 17-29.‏

Fujita, Y., Taniguchi, Y., Shinkai, S., Tanaka, M., & Ito, M. (2016). Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatrics & gerontology international, 16, 17-29.‏

Gilmour, D., & Sykes, A. J. (1951). Westergren and Wintrobe methods of estimating ESR compared. British medical journal, 2(4746), 1496.‏

Gorial, F., Ahmad, W. S., & Abbood, H. S. (2021). Prevalence and impact of fibromyalgia on disease activity in a sample of Iraqi patients with rheumatoid arthritis. Archives of Medical Science-Civilization Diseases, 6(1), 125-131.‏

Hajian-Tilaki, K., Heidari, B., & Bakhtiari, A. (2020). Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholestrol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study. Caspian journal of internal medicine, 11(1), 53.‏

Halacoglu, J., & Shea, L. A. (2020). Cardiovascular risk assessment and therapeutic implications in rheumatoid arthritis. Journal of cardiovascular translational research, 13(5), 878-890.‏

Hannawi, S., Hannawi, H., & Al Salmi, I. (2020). Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis. Hypertension Research, 43(9), 982-984.‏

Hassan, S. B., Abdullah, H. N., & Zakair, K. Y. (2022). The Role of IL-37 as an Anti-Inflammatory Biomarker in some Iraqi Rheumatoid Arthritis Patients and Its Correlation with DAS28. Journal of Techniques, 4(Special Issue), 123-127.‏

He, Y. W., & He, C. S. (2022). Association of growth and differentiation factor 15 in rheumatoid arthritis. Journal of Inflammation Research, 1173-1181.‏

Higashi, Y., Sukhanov, S., Anwar, A., Shai, S. Y., & Delafontaine, P. (2012). Aging, atherosclerosis, and IGF-1. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 67(6), 626-639.‏

Ho, J. E., Mahajan, A., Chen, M. H., Larson, M. G., McCabe, E. L., Ghorbani, A., ... & Wang, T. J. (2012). Clinical and genetic correlates of growth differentiation factor 15 in the community. Clinical chemistry, 58(11), 1582-1591.‏

Ji, X., Zhao, L., Ji, K., Zhao, Y., Li, W., Zhang, R., ... & Yan, C. (2017). Growth differentiation factor 15 is a novel diagnostic biomarker of mitochondrial diseases. Molecular neurobiology, 54, 8110-8116.‏

Jiang, J., Wen, W., & Sachdev, P. S. (2016). Macrophage inhibitory cytokine-1/growth differentiation factor 15 as a marker of cognitive ageing and dementia. Current opinion in psychiatry, 29(2), 181-186.‏

Jiang, W. W., Zhang, Z. Z., He, P. P., Jiang, L. P., Chen, J. Z., Zhang, X. T., ... & Ouyang, X. P. (2021). Emerging roles of growth differentiation factor 15 in brain disorders. Experimental and Therapeutic Medicine, 22(5), 1-11.‏

Karahan, A. Y., Kucuk, A. D. E. M., Balkarli, A. Y. S. E., Kayhan, F., Ozhan, N., Nas, O., ... & Kucuksen, S. (2016). Alexithymia, depression, anxiety levels and quality of life in patients with rheumatoid arthritis. Acta Medica Mediterranea, 32, 1021-28.‏

Kempf, T., Guba-Quint, A., Torgerson, J., Magnone, M. C., Haefliger, C., Bobadilla, M., & Wollert, K. C. (2012). Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. European Journal of Endocrinology, 167(5), 671-678.‏

Khadim, R. M., & Al-Fartusie, F. S. (2021, March). Evaluation of liver function and lipid profiles in Iraqi patients with rheumatoid arthritis. In Journal of Physics: Conference Series (Vol. 1853, No. 1, p. 012040). IOP Publishing.‏

Khalil, M. E., Elhanafy, M. S., Eigela, S. E., Nasr, H. E., & ELgendy, M. E. (2020). Serum GDF-15 Level in Rheumatoid Arthritis and Relation to Disease Activity and Severity. Benha Journal of Applied Sciences, 5(4 part (1)), 131-134.‏

Khater, E. S., & Al Sheik, M. F. (2022). Clinical implications of autoantibodies to extractable nuclear antigens in rheumatoid arthritis patients in tertiary care hospital in Riyadh, Saudi Arabia. Egypt J Immunol, 29(2), 87-95.‏

Korkmaz, S., sirin, F. B., Ayvaz çelik, H. H., Erturan, I., &Yildirim, M. (2022). Could growth differentiation factor-15 be a new inflammatory pathway in psoriasis vulgaris. Medical Journal of Suleyman Demirel University, 29(4).‏

Kugyelka, R., Kohl, Z., Olasz, K., Mikecz, K., Rauch, T. A., Glant, T. T., & Boldizsar, F. (2016). Enigma of IL-17 and Th17 cells in rheumatoid arthritis and in autoimmune animal models of arthritis. Mediators of inflammation, 2016.‏  https://doi.org/10.1155/2016/6145810.

Kypreos, K. E., Bitzur, R., Karavia, E. A., Xepapadaki, E., Panayiotakopoulos, G., & Constantinou, C. (2019). Pharmacological management of dyslipidemia in atherosclerosis: limitations, challenges, and new therapeutic opportunities. Angiology, 70(3), 197-209.‏

Lee, J. E., Kim, I. J., Cho, M. S., & Lee, J. (2017). A case of rheumatoid vasculitis involving hepatic artery in early rheumatoid arthritis. Journal of Korean medical science, 32(7), 1207.‏

Lopez, J. (2013). Carl A. Burtis, Edward R. Ashwood and David E. Bruns (eds): Tietz Textbook of Clinical Chemistry and Molecular Diagnosis Elsevier, St. Louis, USA, 2012, 2238 pp, 909 illustrations. ISBN: 978-1-4160-6164-9.‏

Luma Qasim Ali, Firas Salih Abdulhadi, Ban Talib El-Haboby et al., (2024). Postmenopausal Hormone, Hematology and Immune Modulation in Rheumatoid Arthritis Patients, Journal of Angiotherapy, 8(3), 1-9, 9587

Madhuvan, H. S., Rangaswamaiah, H., & Manigandan, C . (2022). Association of adiponectin levels with disease activity score, RA factor and ESR in rheumatoid arthritis patients.‏

Mahdi, K. S., Hussein, D. M., Dabbi, M. A., Al-Imari, M. J., Obaid, R. H., Hamad, M. H., ... & Abdulabbas, H. S. (2023). The Correlation Study between Rheumatoid Arthritis and Obesity in Babylon Province. The Egyptian Journal of Hospital Medicine, 90(1), 401-406.‏

Mahtta, D., Gupta, A., Ramsey, D. J., Al Rifai, M., Mehta, A., Krittanawong, C., ... & Virani, S. S. (2020). Autoimmune rheumatic diseases and premature atherosclerotic cardiovascular disease: an analysis from the VITAL registry. The American Journal of Medicine, 133(12), 1424-1432.‏

McInnes, I. B., & Schett, G. (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology, 7(6), 429-442.‏

Mohammed, N. U. G., Khaleel, F. M., & Gorial, F. I. (2022). The role of serum chitinase-3-like 1 protein (YKL-40) level and its correlation with proinflammatory cytokine in patients with rheumatoid arthritis. Baghdad Science Journal, 19(5), 1014-1014.‏

Mohammed, T. S., Maroof, R. E., & Al-Hafidh, A. H. (2022). Rheumatoid Arthritis Effects on Kidney and Liver and their Correlations with CDAI. Journal of Techniques, 4(Special Issue), 116-122.‏

Park, Y. J., Cho, C. S., Emery, P., & Kim, W. U. (2013). LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study. PloS one, 8(7), e68975.‏

Piva, S. J., Duarte, M. M., Da Cruz, I. B., Coelho, A. C., Moreira, A. P. L., Tonello, R., ... & Moresco, R. N. (2011). Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clinical biochemistry, 44(4), 345-347.‏

Poddar, A., Behera, D. D., & Ray, S. (2016). Serum alkaline phosphatase activity & serum calcium levels: an assessment tool for disease activity in rheumatoid arthritis. IJBAMR, 5(4), 1324.‏

Popa, C. D., Arts, E., Fransen, J., & van Riel, P. L. (2012). Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators of inflammation, 2012.‏  https://doi.org/10.1155/2012/785946.

Popescu, D., Rezus, E., Badescu, M. C., Dima, N., Seritean Isac, P. N., Dragoi, I. T., & Rezus, C. (2023). Cardiovascular risk assessment in rheumatoid arthritis: accelerated atherosclerosis, new biomarkers, and the effects of biological therapy. Life, 13(2), 319.‏

Ralston, S. H., Penman, I. D., Strachan, M. W., & Hobson, R. (Eds.). (2018). Davidson's Principles and Practice of Medicine: Davidson's Principles and Practice of Medicine E-Book. Elsevier Health Sciences.‏

Rezu?, E., Macovei, L. A., Burlui, A. M., Cardoneanu, A., & Rezu?, C. (2021). Ischemic heart disease and rheumatoid arthritis—two conditions, the same background. Life, 11(10), 1042.‏

Rørholm Pedersen, L., Frestad, D., Mide Michelsen, M., Dam Mygind, N., Rasmusen, H., Elena Suhrs, H., & Prescott, E. (2016). Risk factors for myocardial infarction in women and men: a review of the current literature. Current pharmaceutical design, 22(25), 3835-3852.‏

Scherer, H. U., Häupl, T., & Burmester, G. R. (2020). The etiology of rheumatoid arthritis. Journal of autoimmunity, 110, 102400.‏

Schettler, G., & Nussel, E. (1975). Method for triglycerides. Aeb. Med. Soz. Med. Prav. Med, 10(25).‏

Schwarz, A., Kinscherf, R., & Bonaterra, G. A. (2023). Role of the Stress-and Inflammation-Induced Cytokine GDF-15 in Cardiovascular Diseases: From Basic Research to Clinical Relevance. Reviews in Cardiovascular Medicine, 24(3), 81.‏

Shafaghi, A., Mansour-Ghanaei, F., Rostamnejad, M., Maafi, A. A., Haji-Abbasi, A., & Froutan, H. (2014). Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity. Medical Journal of the Islamic Republic of Iran, 28, 76.‏

Shen, R., Ren, X., Jing, R., Shen, X., Chen, J., Ju, S., & Yang, C. (2015). Rheumatoid factor, anti-cyclic citrullinated peptide antibody, C-reactive protein, and erythrocyte sedimentation rate for the clinical diagnosis of rheumatoid arthritis. Laboratory medicine, 46(3), 226-229.‏

Simm, A., Nass, N., Bartling, B., Hofmann, B., Silber, R. E., & Navarrete Santos, A. (2008). Potential biomarkers of ageing.‏

Skogh, T., Gustafsson, D., Kjellberg, M., & Husberg, M. (2003). Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate. Annals of the rheumatic diseases, 62(7), 681-682.‏

Spanakis, E., Sidiropoulos, P., Papadakis, J., Ganotakis, E., Katsikas, G., Karvounaris, S., ... & Boumpas, D. T. (2006). Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. The Journal of Rheumatology, 33(12), 2440-2446.‏

Sproston, N. R., & Ashworth, J. J. (2018). Role of C-reactive protein at sites of inflammation and infection. Frontiers in immunology, 9, 342848.‏

Sulaiman, F. N., Wong, K. K., Ahmad, W. A. W., & Ghazali, W. S. W. (2019). Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients. Medicine, 98(12), e14945.‏

Swirski, F. K., Libby, P., Aikawa, E., Alcaide, P., Luscinskas, F. W., Weissleder, R., & Pittet, M. J. (2007). Ly-6C hi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. The Journal of clinical investigation, 117(1), 195-205.‏

Tanrikulu, O., Sariyildiz, M. A., Batmaz, I., Yazmalar, L., Polat, N., Kaplan, I., & Çevik, R. (2017). Serum GDF-15 level in rheumatoid arthritis: relationship with disease activity and subclinical atherosclerosis. Acta reumatologica portuguesa, (1).‏

Targonska-Stepniak, B., Piotrowski, M., Zwolak, R., Drelich-Zbroja, A., & Majdan, M. (2018). Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis. Cardiovascular ultrasound, 16, 1-8.‏

Taskinen, M. R. (2003). Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia, 46, 733-749.‏

Tecer, D., Sunar, I., Ozdemirel, A. E., Tural, R., Kucuksahin, O., Dincel, A. S., & Ataman, S. (2019). Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?. Advances in Rheumatology, 59, 49.‏

Tishkowski, K., & Gupta, V. (2020). Erythrocyte sedimentation rate.‏

Toosi, T. D., Rostamiyan, A., Moharrami, K., Movassaghi, S., Nakhjavani, M., & Norooznezhad, A. H. (2018). Lipid profile changes in rheumatoid arthritis patients: Investigation of different affecting factors. Acta Medica Iranica, 665-670.‏

Turesson, C., Jacobsson, L. T., & Matteson, E. L. (2008). Cardiovascular co-morbidity in rheumatic diseases. Vascular health and risk management, 4(3), 605-614.‏

Tziomalos, K., Athyros, V. G., Karagiannis, A., Kolovou, G. D., & Mikhailidis, D. P. (2009). Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Current drug targets, 10(4), 320-327.‏

Unsicker, K., Spittau, B., & Krieglstein, K. (2013). The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine & growth factor reviews, 24(4), 373-384.‏

Urman, A., Taklalsingh, N., Sorrento, C., & McFarlane, I. M. (2018). Inflammation beyond the joints: rheumatoid arthritis and cardiovascular disease. Scifed J Cardiol, 2(3), 1000019.‏

Venetsanopoulou, A. I., Pelechas, E., Voulgari, P. V., & Drosos, A. A. (2020). The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatology international, 40(8), 1181-1191.‏

Vergès, B. (2015). Pathophysiology of diabetic dyslipidaemia: where are we?. Diabetologia, 58(5), 886-899.‏

Vila, G., Riedl, M., Anderwald, C., Resl, M., Handisurya, A., Clodi, M., ... & Luger, A. (2011). The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clinical Chemistry, 57(2), 309-316.‏

Ward, M. M. (2004). Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. The Journal of Rheumatology, 31(5), 884-895.‏

Wilson, P. W. (1998). Why treat dyslipidemia?. Saudi medical journal, 19(4), 376-381.‏

Xia, T., Zheng, X. F., Qian, B. H., Fang, H., Wang, J. J., Zhang, L. L., ... & Zhao, D. B. (2015). Plasma interleukin-37 is elevated in patients with rheumatoid arthritis: its correlation with disease activity and Th1/Th2/Th17-related cytokines. Disease markers, 2015.‏

Xiao, Q. A., He, Q., Zeng, J., & Xia, X. (2022). GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease. Biomedicine & Pharmacotherapy, 146, 112582.‏

Xu, W. D., Su, L. C., He, C. S., & Huang, A. F. (2018). Plasma interleukin-38 in patients with rheumatoid arthritis. International immunopharmacology, 65, 1-7.‏

Xu, W. D., Wu, Q., He, Y. W., Huang, A. F., Lan, Y. Y., Fu, L., ... & Liu, X. Y. (2021). Gene polymorphisms of LGALS2, LGALS3 and LGALS9 in patients with rheumatoid arthritis. Cellular Immunology, 368, 104419.‏

Yalcin, M. M., Altinova, A. E., Akturk, M., Gulbahar, O., Arslan, E., Ors Sendogan, D., ... & Toruner, F. B. (2016). GDF-15 and hepcidin levels in nonanemic patients with impaired glucose tolerance. Journal of Diabetes Research, 2016.‏

Yan, J., Yang, S., Han, L., Ba, X., Shen, P., Lin, W., ... & Chen, Z. (2023). Dyslipidemia in rheumatoid arthritis: the possible mechanisms. Frontiers in Immunology, 14, 1254753.‏

Yap, H. Y., Tee, S. Z. Y., Wong, M. M. T., Chow, S. K., Peh, S. C., & Teow, S. Y. (2018). Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells, 7(10), 161.‏

Yap, H. Y., Tee, S. Z. Y., Wong, M. M. T., Chow, S. K., Peh, S. C., & Teow, S. Y. (2018). Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells, 7(10), 161.‏

Yu, C., Liu, C., Jiang, J., Li, H., Chen, J., Chen, T., & Zhan, X. (2020). Gender differences in rheumatoid arthritis: interleukin-4 plays an important role. Journal of immunology research, 2020.‏

Yücel, H. E., & Ilanbey, B. (2022). The relationship of Growth differentiation factor-15 with renal damage and dyslipidemia in non-albuminuric and albuminuric Type-2 Diabetes Mellitus. Medical Science and Discovery, 9(6), 334-339.‏

Zayed, N. S., Obaid, R. F., & Hamza, A. A. (2022). Association Of Cellular Communication Network Factor 3 (CCN3) With Rheumatoid Arthritis Disease And It's Severity (Case-Control Study). Medical Science Journal for Advance Research, 3(4), 201-208.‏